Horizant still in short supply

A shortage of Horizant continues to impact the WED/RLS community. A medication approved by the FDA in 2011 to treat WED/RLS symptoms, Horiz...


A shortage of Horizant continues to impact the WED/RLS community. A medication approved by the FDA in 2011 to treat WED/RLS symptoms, Horizant (gabapentin enacarbil) has been in short supply since April due to manufacturing delays. Drug developer XenoPort Inc. said it hopes a new stock of Horizant will be in pharmacies in June, but the timing is uncertain. To find the link to the story on our website, click here. You can also read the Xenoport press release on the subject.

The Restless Legs Syndrome Foundation is the leading organization for science-based education and patient services for people suffering from restless legs syndrome (RLS). It is also the only organization with a dedicated research grant program to advance promising research leading to new treatments and a cure. Our goals are simple: increase awareness of RLS, improve treatments, and, through research, find a cure.

You Might Also Like

0 comments

Flickr Images